NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
SNDX
Syndax Pharmaceuticals, Inc.
There isn't enough reported data to score SNDX yet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
SNDX Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Unavailable | |
| Unavailable |
SNDX's revenue is currently healthy, but its profitability is under pressure. There isn't enough data to rate its cash flow and balance sheet.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
SNDX PE Valuation
SNDX has no meaningful PE right now: it lost money over the past year.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
SNDX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
SNDX has the edge over NVO on the outlook, with more favorable earnings and profitability expectations.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over SNDX on earnings quality, reporting a profit while its opponent remains loss making.
SNDX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.36 | +$1.24 |
| Q2 2026 | -$2.51 | +$1.37 |
| Q1 2026 | -$2.79 | +$1.06 |
| Q4 2025 | -$3.29 | +$0.43 |
| Q3 2025 | -$3.60 | +$0.05 |
| Q2 2025 | -$3.88 | -$0.48 |
| Q1 2025 | -$3.85 | -$0.61 |
| Q4 2024 | -$3.72 | -$0.74 |
SNDX is still losing money, but less than at its worst: $2.36 per share over the past year, against $3.88 at its worst in mid-2025.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over SNDX on profitability, with a higher operating margin.
SNDX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $83.3M | +82% |
| Q2 2026 | $72.8M | +92% |
| Q1 2026 | $64.9M | +224% |
| Q4 2025 | $68.7M | +795% |
| Q3 2025 | $45.9M | +267% |
| Q2 2025 | $38M | +985% |
| Q4 2021 | $126.6M | +33209% |
| Q3 2021 | $12.4M | +3165% |
SNDX has the edge over NVO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -50% | +75 points |
| Q2 2026 | -55% | +128 points |
| Q1 2026 | -53% | +365 points |
| Q4 2025 | -91% | +1164 points |
| Q3 2025 | -125% | +591 points |
| Q2 2025 | -183% | +1938 points |
| Q1 2025 | -418% | N/A |
| Q4 2024 | -1255% | N/A |
SNDX's operating margin was −50% last quarter, up 75 points from the same quarter a year ago.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
SNDX has the stronger cash trend. Its trailing FCF is up 4.7% versus its history, compared with NVO at down 14%.
SNDX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$27.3M | +$43.3M |
| Q2 2026 | -$30.3M | +$57.5M |
| Q1 2026 | -$50.3M | +$44.8M |
| Q3 2025 | -$70.5M | -$8.2M |
| Q2 2025 | -$87.8M | -$16.2M |
| Q1 2025 | -$95.2M | -$11.6M |
| Q3 2024 | -$62.3M | -$17.7M |
| Q2 2024 | -$71.6M | -$36.3M |
SNDX has burned cash in almost every quarter: −$178M over the past year, against −$303M the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over SNDX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
SNDX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +799K shares |
| 1 year | +3.7% | +3.2M shares |
| 3 years | +29% | +19.9M shares |
| 5 years | +73% | +37.8M shares |
| Available history | +184% | +58.1M shares |
SNDX has 90M diluted shares, up 3.7% from a year ago.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
SNDX Net Leverage
SNDX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
SNDX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 26.3 | Oversold |
| Stochastic | 5.3 | Oversold |
SNDX's weekly RSI is 26 (oversold) and its Stochastic is 5 (oversold).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
SNDX PE vs Healthcare Sector
| Metric | SNDX | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
SNDX has no meaningful PE right now: it lost money over the past year.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over SNDX on trend strength, trading above more of its moving averages.
SNDX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $14.0 | 32% below |
| 20 week MA | $17.8 | 46% below |
| 50 week MA | $19.8 | 52% below |
| 100 week MA | $16.6 | 42% below |
| 200 week MA | $18.4 | 48% below |
SNDX is in a downtrend: it's below all five of its weekly moving averages, and 48% below its 200-week average.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over SNDX on returns for 2026, with the stronger performance.
SNDX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $8.94 | $24.2 | +171% |
| 2021 | $24.2 | $22.5 | -7.1% |
| 2022 | $22.5 | $24.3 | +8.1% |
| 2023 | $24.3 | $21.6 | -11% |
| 2024 | $21.6 | $12.8 | -41% |
| 2025 | $12.8 | $21.3 | +67% |
| 2026 YTD | $21.3 | $9.54 | -55% |
SNDX's yearly returns have swung widely, from +171% in 2020 to −41% in 2024. It's down 55% so far in 2026.